European Commission: Commission proposes to purchase up to 300 million additional doses of BioNTech-Pfizer vaccine

The European Commission today proposed to the EU Member States to purchase an additional 200 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer, with the option to acquire another 100 million doses.

This would enable the EU to purchase up to 600 million doses of this vaccine, which is already being used across the EU.

The additional doses will be delivered starting in the second quarter of 2021.

The EU has acquired a broad portfolio of vaccines with different technologies. It has secured up to 2.3 billion doses from the most promising vaccine candidates for Europe and its neighbourhood.

In addition to the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on 6 January 2021. Other vaccines are expected to be approved soon.

This vaccine portfolio would enable the EU not only to cover the needs of its whole population, but also to supply vaccines to neighbouring countries.

Source


Tags assigned to this article:
coronaviruscovid-19

You may have an interest in also reading…

UN News: Generations of progress for women and girls could be lost to COVID pandemic, UN chief warns

Highlighting the disproportionate and devastating socio-economic impact of COVID-19 on women and girls globally, The UN chief António Guterres called

The World Bank: The Global Economy: on Track for Strong but Uneven Growth as COVID-19 Still Weighs

A year and a half since the onset of the COVID-19 pandemic, the global economy is poised to stage its

World Bank: Beyond the Pandemic: Harnessing the Digital Revolution to Set Food Systems on a Better Course

By: Julian Lampietti, Ghada El Abed, and Kateryna Schroeder One of the most striking images of the coronavirus pandemic is the contrast